BCDA vs. XLO, FBLG, FBRX, OKYO, ALVR, DYAI, CNTB, RNTX, PEPG, and XFOR
Should you be buying BioCardia stock or one of its competitors? The main competitors of BioCardia include Xilio Therapeutics (XLO), FibroBiologics (FBLG), Forte Biosciences (FBRX), OKYO Pharma (OKYO), AlloVir (ALVR), Dyadic International (DYAI), Connect Biopharma (CNTB), Rein Therapeutics (RNTX), PepGen (PEPG), and X4 Pharmaceuticals (XFOR). These companies are all part of the "pharmaceutical products" industry.
BioCardia vs.
BioCardia (NASDAQ:BCDA) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.
BioCardia has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the S&P 500.
20.6% of BioCardia shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 20.0% of BioCardia shares are held by insiders. Comparatively, 5.2% of Xilio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, BioCardia had 6 more articles in the media than Xilio Therapeutics. MarketBeat recorded 6 mentions for BioCardia and 0 mentions for Xilio Therapeutics. BioCardia's average media sentiment score of 0.24 beat Xilio Therapeutics' score of 0.00 indicating that BioCardia is being referred to more favorably in the media.
BioCardia received 5 more outperform votes than Xilio Therapeutics when rated by MarketBeat users. However, 75.00% of users gave Xilio Therapeutics an outperform vote while only 60.71% of users gave BioCardia an outperform vote.
BioCardia has higher earnings, but lower revenue than Xilio Therapeutics. BioCardia is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks.
BioCardia presently has a consensus target price of $25.00, suggesting a potential upside of 1,202.08%. Xilio Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 432.20%. Given BioCardia's stronger consensus rating and higher probable upside, equities analysts plainly believe BioCardia is more favorable than Xilio Therapeutics.
Xilio Therapeutics has a net margin of 0.00% compared to BioCardia's net margin of -1,999.77%. BioCardia's return on equity of 0.00% beat Xilio Therapeutics' return on equity.
Summary
BioCardia beats Xilio Therapeutics on 11 of the 18 factors compared between the two stocks.
Get BioCardia News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioCardia Competitors List
Related Companies and Tools
This page (NASDAQ:BCDA) was last updated on 4/20/2025 by MarketBeat.com Staff
